Low incidence of hepatotoxicity associated with long-term, low-dose oral XXXX in treatment of @entity1569 , psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio.

@entity1 @entity82 @entity1560 @entity1569 @entity66 @entity167 @entity409 @entity1500 @entity1499
Thirty @entity1 with @entity1569 or other @entity66 had liver biopsies done before treatment with low-dose @entity1499 , 15 mg/week, and then at one- to two-year intervals as long as they continued the @entity1499 . All @entity1 were symptomatically improved on this regimen. The 15 @entity1 who had normal liver biopsies at the start of the study had normal biopsies after @entity1499 . Fifteen others had minor hepatic histologic abnormalities before treatment. Eleven @entity1 had @entity1560 . Ten showed no significant change after treatment while one had increased fat and portal @entity82 on a fourth liver biopsy done seven years after @entity1500 was begun. This last @entity1 , a former @entity167 abuser, continued @entity1499 and showed no further worsening at 8 years. The remaining four had portal @entity82 before treatment. One @entity1 had less @entity82 after @entity1499 , two @entity1 slightly more @entity82 , and one a marked increase in portal @entity82 . No @entity1 developed @entity82 or clinical @entity409 . Our results suggest that in the absence of @entity167 consumption, low-dose weekly @entity1499 treatment rarely causes clinically significant @entity409 .
